geographic atrophy

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

R&D

pharmaphorum podcast Episode 253, Lance Baldo, Beacon Therapeutics

Looking to gene therapy for ocular diseases, with Lance Bald...

Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

News

A woman hides her face behind her hands, revealing her right eye

Ocugen shares fall, despite positive eye disorder trial

A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.

News

Joy as retinal implant restores sight in geographic atrophy

A wireless retinal implant already filed for approval has been shown to restore vision in patients with eye disease geographic atrophy.

News

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.

News

Boehringer advances oral therapy for geographic atrophy

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

RNAi biotech City hauls in $200m in upsized IPO

Looking to gene therapy for ocular diseases, with Lance Bald...

Ocugen shares fall, despite positive eye disorder trial

Joy as retinal implant restores sight in geographic atrophy

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Boehringer advances oral therapy for geographic atrophy

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

geographic atrophy

Editor's Picks